Stephen H. Caldwell

Stephen H. Caldwell

Auto-generated profile, based on publicly available information

Stephen H. Caldwell

University of Virgina, Charlottesville, VA, United States

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2023 in Hepatology
Verified
Journal Article
Closed access
MRMary E. Rinella
Mary E. Rinella
BNBrent A. Neuschwander-Tetri
Brent A. Neuschwander-Tetri
MSMohammad Shadab Siddiqui
Mohammad Shadab Siddiqui
MAManal F Abdelmalek
Manal F Abdelmalek
SCStephen Caldwell
Stephen Caldwell
RLRohit Loomba
Rohit Loomba

26 April 2004 in Hepatology
Verified
Journal Article
Open access
PDF file
TLTri H. Le
Tri H. Le
SCStephen H. Caldwell
Stephen H. Caldwell
JRJan A. Redick
Jan A. Redick
BSBonnie L. Sheppard
Bonnie L. Sheppard
CDChristine A. Davis
Christine A. Davis
TPTheresa C. Peterson
Theresa C. Peterson
Megamitochondria with crystalline inclusions (MMC) have been previously described in nonalcoholic fatty liver; however, their distribution within hepatic zones is unknown. We sought to determine this distribution from the core liver biopsy specimens of 31 patients: 8 males and 23 females, age range 21 to 72 years. Twenty-nine showed evidence of nonalcoholic steatohepatitis (NASH) on biopsy with steatosis, inflammation, varying degree of fibrosis, ballooned hepatocytes, and Mallory hyaline, and two patients had cryptogenic cirrhosis thought to represent “burned out” NASH. Identified by transmission electron microscopy, the abundance of MMC was compared between low-stage (fibrosis stages 1 and 2) and high-stage (fibrosis stages 3 and 4) groups and between zones with or without difference in fibrosis stage. Regardless of stage, the MMC were distributed equally in all zones and were abundant similarly in low- and high-stage groups. This abundance did not correlate with the degree of oxidative stress (4-hydroxynonenal staining) or with the abundance of ballooned hepatocytes. Consistent with age as a risk factor for more severe disease, the median age for the low-stage group was significantly lower than that of the high-stage group (P = .003). In conclusion, in NASH, the MMC seem to be distributed randomly among zones and without variation in abundance, regardless of the fibrosis stage. The exact function of these structures remains to be defined. In this study, their presence did not seem to correlate with the light microscopic injury pattern represented by ballooned hepatocytes or degree of oxidative stress defined by immunostaining for 4-hydroxynonenal. (Hepatology 2004;39:1423-1429.)

9 February 2024 in Journal of Hepatology
Verified
Journal Article
Open access
Amedeo LonardoAmedeo Lonardo
Amedeo Lonardo
FBFernando Bril
Fernando Bril
SCStephen H. Caldwell
Stephen H. Caldwell
MEMohammed Eslam
Mohammed Eslam
JFJian-Gao Fan
Jian-Gao Fan
JGJacob George
Jacob George

1 July 2009 in Journal of Clinical Gastroenterology
Verified
Journal Article
Closed access
CACurtis K. Argo
Curtis K. Argo
JIJulia C. Iezzoni
Julia C. Iezzoni
AAAbdullah M. S. Al-Osaimi
Abdullah M. S. Al-Osaimi
SCStephen H. Caldwell
Stephen H. Caldwell
Although of unproven benefit for nonalcoholic steatohepatitis (NASH), thiazolidinediones (TZDs) have emerged as a promising therapy. Little evidence exists, however, regarding sustained effects of TZDs in NASH after drug discontinuation. A recent clinical study suggests that relapse of NASH pathophysiology is inevitable and that lifelong therapy may be needed to maintain histologic response. We reviewed extended follow-up data of NASH patients previously treated with troglitazone to evaluate the influence of weight and physical activity on clinical and histologic parameters related to NASH recurrence. After medical record review, 9 of 10 patients had complete data for follow-up and 5 had an extended follow-up biopsy 3 years or more after discontinuing troglitazone therapy. In contrast to recent work showing relapse of NASH to be nearly universal after discontinuation of TZD therapy, 2 of our patients had 1-stage improvement in fibrosis, normal aminotransferases, and absence of diabetes after median follow-up of 37 months after discontinuation of troglitazone. Both patients had sustained exercise programs and interval body mass index reduction. In contrast, active steatohepatitis, progression of fibrosis, and requirement of antidiabetic medications were seen in patients unable to achieve lifestyle modifications. We conclude that sustained histologic response after short-term TZD therapy for NASH is not invariably lost after medication discontinuation but rather is intimately related to sustained changes in lifestyle, particularly physical activity. Activity and diet in the setting of thiazolidinedione or other drug therapy of NASH is an essential consideration that warrants careful incorporation into future drug trials.

1 March 2017 in Annals of Hepatology
Verified
Journal Article
Open access
ASAmy R. Shriver
Amy R. Shriver
SRSean R. Rudnick
Sean R. Rudnick
NINicolas M. Intagliata
Nicolas M. Intagliata
AWAmanda M. Wang
Amanda M. Wang
SCStephen H. Caldwell
Stephen H. Caldwell
PNPatrick G. Northup
Patrick G. Northup
Intrahepatic cholestasis of pregnancy (ICP) is a severe liver disease uniquely occurring during pregnancy. In this study we aimed to identify novel biomarker for the diagnosis of ICP in Chinese population. 50 healthy pregnant women, 50 mild ICP patients and 48 severe ICP patients were enrolled for this study. Liver function tests, including serum total bilirubin, direct bilirubin, alanine transaminase, aspartate aminotransferase and cholyglycine, were performed in all participants. After an overnight fast serum levels of total bile acids (TBA), matrix metalloproteinase (MMP)-2 and MMP-9 were measured, and their correlation with liver function tests were analyzed. The observed increase in serum TBA in ICP patients was not statistically significant which made it unreliable for diagnosis of ICP in Chinese population. On the other hand, both MMP-2 and MMP-9 serum levels exhibited a progressive and significant elevation in mild and severe ICP patients compared with healthy pregnant women, which also positively correlated with liver function tests. Serum levels of both MMP-2 and MMP-9 could be reliably used as laboratory abnormalities for accurate diagnosis and sensitive grading of ICP in Chinese population.

1 January 2010 in Digestive Diseases
Verified
Journal Article
Closed access
PDF file
AEAnnette Erhardt
Annette Erhardt
GTGisa Tiegs
Gisa Tiegs
CSChristian P. Strassburg
Christian P. Strassburg
MTMichael Trauner
Michael Trauner
Peter FickertPeter Fickert
Peter Fickert
Matthias Hardtke-WolenskiMatthias Hardtke-Wolenski
Matthias Hardtke-Wolenski